Weekly Rundown: Merck advances once-monthly HIV pill to Phase 3 FDA rejections and safety concerns, a once-monthly HIV PrEP pill, developments in neuroscience drug development, and more led the news this week.

https://www.drugdiscoverynews.com/weekly-rundown-merck-advances-once-monthly-hiv-pill-to-phase-3-16504?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-_6PLMnalsXT8A5tIf4ekrdbekqEbthuM1GptWy1Pr1L7UELObC3z61f6l9rMkgvtGWICZzhLLhcogXGMPZtYsUV-hLIA&_hsmi=371923462&utm_content=371923462&utm_source=hs_email